Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Bilateral Breast Carcinoma 1

Interventions

Fulvestrant 83Letrozole 77Paclitaxel 76pembrolizumab 72Specimen Handling 66Trastuzumab 62Carboplatin 57Magnetic Resonance Spectroscopy 51ribociclib 49Capecitabine 48Anastrozole 47pertuzumab 46palbociclib 43exemestane 40abemaciclib 40Cyclophosphamide 40Tamoxifen 39Biopsy 38Docetaxel 30trastuzumab deruxtecan 29Taxes 28Radiotherapy 28Gemcitabine 25Blood Specimen Collection 25130-nm albumin-bound paclitaxel 25olaparib 22Surveys and Questionnaires 22Standard of Care 22sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epothilones × Breast × 90 days × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡